Skip to main content

Gollob Jared's Form 4 filing

Kymera Therapeutics, Inc. (KYMR) · filed Nov 2, 2021

Accession no.
0000899243-21-042437
Filed
Nov 2, 2021
Trade date
Nov 1-2, 2021
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 10 non-derivative transactions and 3 derivative transactions. Open-market sales total $3.57M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gollob JaredCIK 0001821198Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 1, 2021Common StockMOption exerciseAcquired+20,000$1.31+$26,20062,547Direct
Nov 1, 2021Common StockMOption exerciseAcquired+4,607$2.08+$9,582.5667,154Direct
Nov 1, 2021Common StockSSaleDisposed−7,387$60.40F2−$446,174.859,767Direct
Nov 1, 2021Common StockSSaleDisposed−15,134$61.50F3−$930,74144,633Direct
Nov 1, 2021Common StockSSaleDisposed−15,911$62.34F4−$991,891.7428,722Direct
Nov 1, 2021Common StockSSaleDisposed−4,065$63.17F5−$256,786.0524,657Direct
Nov 2, 2021Common StockMOption exerciseAcquired+14,996$2.08+$31,191.6839,653Direct
Nov 2, 2021Common StockSSaleDisposed−8,514$62.89F6−$535,445.4631,139Direct
Nov 2, 2021Common StockSSaleDisposed−5,280$63.50F7−$335,28025,859Direct
Nov 2, 2021Common StockSSaleDisposed−1,202$64.34F8−$77,336.6824,657Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 1, 2021Common StockMOption exerciseDisposed−20,000$0.00$040,007Direct
Nov 1, 2021Common StockMOption exerciseDisposed−4,607$0.00$0133,808Direct
Nov 2, 2021Common StockMOption exerciseDisposed−14,996$0.00$0118,812Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.01 to $62.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.03 to $63.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.03 to $63.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.13 to $63.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.13 to $64.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.13 to $64.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)